Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Survival Benefit with Standard-Dose Decitabine Versus Standard-Dose Azacitidine in Patients with Lower-Risk Myelodysplastic Syndromes

Byung-Hyun Lee, MD, Ka-Won Kang, MD, Min Ji Jeon, MD, Eun Sang Yu, MD, Dae Sik Kim, MD PhD, Hojoon Choi, MD, Se Ryun Lee, MD PhD, Hwa Jung Sung, MD PhD, Yong Park, MD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3099.

https://doi.org/10.1182/blood-2018-99-115694

Published: 2018

Journal Articles

One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea

Yong Park, MD, Dae Sik Kim, MD PhD, Ka-Won Kang, MD, Byung-Hyun Lee, MD, Eun Sang Yu, MD, Min Ji Jeon, MD, Hojoon Choi, MD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Chul Won Choi, MD PhD, Kihyun Kim, MD PhD, Byung Soo Kim, MD PhD, Seok Jin Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2018-99-115625

Published: 2018

Journal Articles

Immature Platelet Fraction Based Diagnostic Predictive Model for Immune Thrombocytopenic Purpura

Min Ji Jeon, MD, Hojoon Choi, MD, Eun Sang Yu, MD, Ka-Won Kang, MD, Byung-Hyun Lee, MD, Dae Sik Kim, MD PhD, Yong Park, MD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2018) 132 (Supplement 1): 1149.

https://doi.org/10.1182/blood-2018-99-117754

Published: 2018

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

The Potential of Exosomes Derived from Chronic Myelogenous Leukemia Cells As Biomarker Based on the BCR-ABL mRNA Transcript

Ka-Won Kang, MD, Jik-han Jung, Woojune Hur, Jaena Park, Hyunku Shin, ByeongHyeon Choi, Hyesun Jeong, Dae Sik Kim, MD PhD, Eun Sang Yu, MD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Seok Jin Kim, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD, Hyun Koo Kim, MD PhD, Sunghoi Hong, PhD, Ji-ho Park, PhD, Yeonho Choi, PhD, Yong Park, MD PhD

Blood (2017) 130 (Supplement 1): 2883.

https://doi.org/10.1182/blood.V130.Suppl_1.2883.2883

Published: 2017

Journal Articles

the Safety and Efficacy of Pomalidomide in Combination with Cyclophosphamide and Dexamethasone (PCD) in the Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-Labeled, Multicenter Phase II Study

Ho Sup Lee, MD, Chang-Ki Min, MD PhD, Kihyun Kim, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, Dok Hyun Yoon, MD PhD, Cheolwon Suh, MD PhD, Ho-Jin Shin, MD, Yeung-Chul Mun, MD PhD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, MD PhD, Hye Jin Kang, MD PhD, Sung-Soo Yoon, MD PhD

Blood (2017) 130 (Supplement 1): 1834.

https://doi.org/10.1182/blood.V130.Suppl_1.1834.1834

Published: 2017

Journal Articles

Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party

Blood (2017) 130 (Supplement 1): 4257.

https://doi.org/10.1182/blood.V130.Suppl_1.4257.4257

Published: 2017

Journal Articles

Routine Imaging for Surveillance in Patients with Aggressive Non-Hodgkin Lymphoma in Complete Remission after Frontline Chemotherapy

Ka-Won Kang, MD, Dae Sik Kim, MD PhD, Eun Sang You, MD, Yong Park, MD PhD, Se Ryeon Lee, Hwa Jung Sung, MD PhD, Seok Jin Kim, Chul Won Choi, MD PhD, Byung Soo Kim

Blood (2016) 128 (22): 3041.

https://doi.org/10.1182/blood.V128.22.3041.3041

Published: 2016

Journal Articles

Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome

Hawk Kim, MD PhD, Je-Hwan Lee, MD PhD, Won-Sik Lee, MD, Inho Kim, Joon Ho Moon, MD, PhD, Chul Won Choi, MD PhD, Ho Sup Lee, MD PhD, Jinny Park, Ho-Jin Shin, Kyoung Ha Kim, MD, Su-Hee Cho, MD PhD, Sung-Yong Kim, MD, Yoo-Jin Kim

Blood (2015) 126 (23): 1687.

https://doi.org/10.1182/blood.V126.23.1687.1687

Published: 2015

Journal Articles

Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies

Ka-Won Kang, MD, Yong Park, MD PhD, Dae Sik Kim, MD PhD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Seok Jin Kim, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2015) 126 (23): 4889.

https://doi.org/10.1182/blood.V126.23.4889.4889

Published: 2015

Journal Articles

High-Dose Cytarabine Alone Versus Cytarabine Plus Anthracycline for Consolidation Therapy in Non-Promyelocytic Acute Myeloid Leukemia

Sung-Hyun Kim, So Yeon Kim, Ji Hyun Lee, MD PhD, Suee Lee, Sung Yong Oh, Hyo-Jin Kim, Dae Sik Kim, MD, Ka-Won Kang, MD, Se Ryeon Lee, MD PhD, Yong Park, MD PhD, Hwa Jung Sung, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2015) 126 (23): 4890.

https://doi.org/10.1182/blood.V126.23.4890.4890

Published: 2015

Journal Articles

Comparable Outcomes with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients with or without Aplastic Anemia in a Prospective Korean PNH Registry

Jun Ho Jang, Jin Seok Kim, MD PhD, Deog-Yeon Jo, MD PhD, Je-Hwan Lee, MD PhD, Chul Won Choi, MD PhD, Hyeoung Joon Kim, MD PhD, Jong-Ho Won, MD PhD, Joo Seop Chung, MD PhD, Hawk Kim, MD PhD, Jae-Hoon Lee, MD PhD, Sang Kyun Sohn, MD PhD, Jeong A Kim, MD PhD, Jong Wook Lee, MD PhD

Blood (2015) 126 (23): 4789.

https://doi.org/10.1182/blood.V126.23.4789.4789

Published: 2015

Journal Articles

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

Blood (2015) 126 (23): 476.

https://doi.org/10.1182/blood.V126.23.476.476

Published: 2015

Journal Articles

Ineffective Corticosteroid Treatment for Hemolysis Management of Paroxysmal Nocturnal Hemoglobinuria

Jong Wook Lee, MD PhD, Jun Ho Jang, MD PhD, Je-Hwan Lee, MD PhD, Deog-Yeon Jo, MD PhD, Jin Seok Kim, Yong Park, MD PhD, Sang Kyun Sohn, MD PhD, Jun Sung Park, MD PhD, Chul Won Choi, MD PhD, Joo Seop Chung, MD PhD, Jae Hoon Lee, MD PhD, Jeong A Kim, MD PhD, Jong-Ho Won, MD PhD

Blood (2014) 124 (21): 5151.

https://doi.org/10.1182/blood.V124.21.5151.5151

Published: 2014

Journal Articles

High-Dose Cytarabine Consolidation (≥1.5 g/m 2 ) Might Have Shown a Better Outcomes Than Intermediate-Dose Cytarabine (1.0 g/m 2 ) Combined With Anthracyclines In AML Patients Who Had Achieved Complete Remissions In The First Induction by Standard 3+7 Regimen

Yong Park, MD, PhD, Ga-won Kang, MD, Dae Sik Kim, MD, Suk-young Lee, MD, Ph.D, Se Ryeon Lee, MD, PhD, Hwa Jung Sung, Chul Won Choi, MD, PhD, Seok Jin Kim, MD, PhD, Myunghyun Nam, MD, PhD, Ji-Seon Choi, MD, PhD, Soo-Young Yoon, MD, PhD, Byung Soo Kim, Insun Kim, MD, PhD

Blood (2013) 122 (21): 2692.

https://doi.org/10.1182/blood.V122.21.2692.2692

Published: 2013

Journal Articles

Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry

Jong Wook Lee, MD, PhD, Jun Ho Jang, MD, PhD, Jin Seok Kim, MD, Je-Hwan Lee, Deog-Yeon Jo, MD, PhD, Yeo-Kyeoung Kim, MD, PhD, Jooseop Chung, MD, PhD, Jeong-A Kim, MD, PhD, Jae Hoon Lee, Chul-Won Choi, MD, PhD, Yong Park, MD, PhD, Jun Sung Park, MD, PhD

Blood (2013) 122 (21): 3720.

https://doi.org/10.1182/blood.V122.21.3720.3720

Published: 2013

Journal Articles

Efficacy Of Ruxolitinib In Korean Myelofibrosis Patients and Cases Complicated TB Lymphadenitis During The Treatment

Yeo-Kyeoung Kim, MD, PhD, Se Ryeon Lee, MD, PhD, Yong Park, MD, PhD, Chul Won Choi, MD, PhD, Soo Jeong Kim, MD, PhD, Ho-Young Yhim, MD, PhD, Inho Kim, Doyeun Oh, MD, PhD, Yeung-Chul Mun, Sung-Nam Lim, MD, PhD, Jeong-A Kim, PhD, MD, Myung-Geun Shin, MD, PhD, Jong-Ho Won, MD, PhD

Blood (2013) 122 (21): 1596.

https://doi.org/10.1182/blood.V122.21.1596.1596

Published: 2013

Journal Articles

Treatment Outcomes and Prognostic Factors of Ifosfamide, Etoposide, Cytarabine, Methotrexate, and Dexamethasone (IVAMdex) Regimen As 3 rd Line (2 nd salvage) Chemotherapy in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Yong Park, Seh Jong Park, Seok Young Lee, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, MD, PhD, Chul Won Choi, MD, PhD, Byung Soo Kim

Blood (2011) 118 (21): 2685.

https://doi.org/10.1182/blood.V118.21.2685.2685

Published: 2011

Journal Articles

Busulfan, Melphalan and Etoposide Followed by Autologous Stem Cell Transplantation on Patients with Non-Hodgkin's Lymphoma: Multicenter Study From Consortium for Improving Survival of Lymphoma (CISL) in Korea

Kyoung Ha Kim, M.D., Won Seog Kim, Sung-Kyu Park, Mark Hong Lee, MD, PhD, Sang Kyun Sohn, Cheolwon Suh, MD, Hye Jin Kang, Chul Won Choi, MD, PhD, Ho Sup Lee, Sung Hwa Bae, Jinny Park, Eunkyung Park, MD, PhD, Jae-Yong Kwak, MD, PhD, Han Jo Kim, Se-Hyung Kim, MD, Jong-Ho Won, MD, PhD

Blood (2011) 118 (21): 2021.

https://doi.org/10.1182/blood.V118.21.2021.2021

Published: 2011

NARROW

Survival Benefit with Standard-Dose Decitabine Versus Standard-Dose Azacitidine in Patients with Lower-Risk Myelodysplastic Syndromes

One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea

Immature Platelet Fraction Based Diagnostic Predictive Model for Immune Thrombocytopenic Purpura

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

The Potential of Exosomes Derived from Chronic Myelogenous Leukemia Cells As Biomarker Based on the BCR-ABL mRNA Transcript

Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party

Routine Imaging for Surveillance in Patients with Aggressive Non-Hodgkin Lymphoma in Complete Remission after Frontline Chemotherapy

Lenalidomide As a Second-Line Therapy after Failure of Hypomethylating Agents in Patients with Myelodysplastic Syndrome

Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies

High-Dose Cytarabine Alone Versus Cytarabine Plus Anthracycline for Consolidation Therapy in Non-Promyelocytic Acute Myeloid Leukemia

Comparable Outcomes with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients with or without Aplastic Anemia in a Prospective Korean PNH Registry

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

Ineffective Corticosteroid Treatment for Hemolysis Management of Paroxysmal Nocturnal Hemoglobinuria

High-Dose Cytarabine Consolidation (≥1.5 g/m 2 ) Might Have Shown a Better Outcomes Than Intermediate-Dose Cytarabine (1.0 g/m 2 ) Combined With Anthracyclines In AML Patients Who Had Achieved Complete Remissions In The First Induction by Standard 3+7 Regimen

Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry

Efficacy Of Ruxolitinib In Korean Myelofibrosis Patients and Cases Complicated TB Lymphadenitis During The Treatment

Treatment Outcomes and Prognostic Factors of Ifosfamide, Etoposide, Cytarabine, Methotrexate, and Dexamethasone (IVAMdex) Regimen As 3 rd Line (2 nd salvage) Chemotherapy in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Busulfan, Melphalan and Etoposide Followed by Autologous Stem Cell Transplantation on Patients with Non-Hodgkin's Lymphoma: Multicenter Study From Consortium for Improving Survival of Lymphoma (CISL) in Korea

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only